NVP 2203
Alternative Names: NVP-2203Latest Information Update: 18 Oct 2023
At a glance
- Originator NVP Healthcare
- Class Antihyperlipidaemics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Hypercholesterolaemia
Most Recent Events
- 30 Jun 2023 Phase-III clinical trials in Hypercholesterolaemia in South Korea (PO) (NCT05856487)
- 11 Jun 2023 NVP Healthcare completes a phase I pharmacokinetics trial (In volunteers) in South Korea (PO) (NCT05725252)
- 12 May 2023 NVP Healthcare plans a phase III trial for Cardiovascular disorder in May 2023 (PO) (NCT05856487)